| 摘要 |
<p>Disclosed are Renin inhibitory peptides of the formula <CHEM> wherein A is, e.g., hydrogen; R<1> is, e.g., hydrogen; R<3> is e.g., C3-6 alkyl; R<4> is e.g., hydrogen; or <CHEM> where R<2> is hydrogen; C1-4 alkyl; aryl; aryl substituted with up to three members selected from the group consisting of C1-4 alkyl, trifluoromethyl, hydroxy, C1-4 alkoxy, fluoro, chloro, bromo, and iodo; or indolyl; R<5> is hydrogen; C1-4 alkyl; hydroxy; or C3-7 cycloalkyl; and B is, e.g., -Y-(CH2)n-R<6> where Y is -NH- or -O-; n is 0 to 5; and R<6> is, e.g., hydrogen; D is, e.g., absent: glycyl; or sarcosyl; and E is absent; OR; NHR; or N (R)2 where R may be the same or different and is hydrogen or C1-4 alkyl; wherein all of the asymmetric carbon atoms have an S configuration, except for those in the A, B and D substituents, which may have an S or R configuration; and a pharmaceutically acceptable salt thereof. Those compounds inhibit renin and are useful for treating various forms of renin-associated hypertension and hyperaldosoeronism.</p> |
